Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.
Verona Pharma PLC (VRNA) is a clinical-stage biopharmaceutical company advancing innovative therapies for chronic respiratory diseases. This page serves as the definitive source for official news, including updates on clinical trials, regulatory milestones, and strategic partnerships.
Investors and researchers can track developments related to key programs like ensifentrine for COPD treatment, with real-time access to press releases about FDA submissions, trial results, and manufacturing collaborations. Our curated collection ensures you never miss critical updates about respiratory therapy innovations.
Explore verified information on phase III trial progress, regulatory communications, and research partnerships with leading medical institutions. All content is sourced directly from company filings and official statements to maintain accuracy.
Bookmark this page for streamlined access to VRNA's latest advancements in treating COPD, cystic fibrosis, and asthma. Check regularly for developments that shape the future of respiratory care.
Verona Pharma (Nasdaq: VRNA) has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025. The company will host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss the financial results and provide a corporate update.
Investors can participate via phone by dialing +1-800-715-9871 (US callers) or +1-646-307-1963 (international callers). A live webcast will be available through the Events and Presentations section on the company's investor webpage, with audio replay accessible for 90 days.
Xeris Biopharma Holdings (Nasdaq: XERS) announced changes to its Board of Directors. Ricki Fairley has resigned effective immediately, while John Schmid will not seek re-election at the 2025 Annual Stockholders Meeting, which will reduce the board size to eight members.
The company has appointed James Brady as a new director to fill the immediate vacancy. Brady brings over thirty years of experience from AstraZeneca, where he held various leadership positions, most recently serving as Chief Financial Officer of MedImmune, AstraZeneca's biologics discovery and development division. He currently serves on the Board of Directors and Audit Committee of Verona Pharma plc (Nasdaq: VRNA).
Verona Pharma (VRNA) has amended its strategic financing agreements with Oaktree Capital Management and OMERS Life Sciences, marking significant changes to its capital structure. The company has:
- Repurchased the Revenue Interest Purchase and Sale Agreement (RIPSA) $100 million obligation
- Increased its term loan facility to $450 million with improved terms
- Borrowed $125 million from an expanded Tranche C, bringing total outstanding debt to $250 million
- Reduced interest rates from 11% to 9.7%, with potential further reduction to 9.35% upon meeting sales milestones
- Gained ability to secure up to $75 million in working capital revolving credit
The refinancing reflects the successful launch and growing prescriptions of Ohtuvayre™ (ensifentrine), their COPD maintenance treatment, providing increased financial flexibility and simplified balance sheet structure.
Verona Pharma (VRNA) reported strong Q4 and full year 2024 results for Ohtuvayre, their first FDA-approved COPD maintenance treatment. Q4 net product sales reached $36.6 million, contributing to full year sales of $42.3 million.
The company highlighted growing prescription momentum, with over 4,600 unique prescribers and approximately 55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025. The drug received its first approval outside the US in Macau.
Financial results show Q4 net loss of $33.8 million and full year net loss of $173.4 million. Cash position remained strong at $399.8 million as of December 31, 2024. The company is advancing Phase 2 programs in bronchiectasis and a fixed-dose combination therapy for COPD, with plans to initiate a Phase 2b trial in H2 2025.
Verona Pharma (Nasdaq: VRNA) has announced its participation in two major healthcare investor conferences in March 2025. The company will present corporate overviews at the TD Cowen 45th Annual Health Care Conference in Boston on March 3 at 11:10 a.m. ET, and at the Leerink Partners 2025 Global Healthcare Conference in Miami on March 10 at 8:40 a.m. ET.
The company specializes in developing treatments for chronic respiratory diseases, with their flagship product Ohtuvayre™ (ensifentrine), the first inhaled COPD maintenance therapy combining bronchodilator and anti-inflammatory properties. Webcasts of both presentations will be available on the company's website.
Verona Pharma (Nasdaq: VRNA) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025. The company will host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the results and provide a corporate update.
The company specializes in developing and commercializing innovative therapies for chronic respiratory diseases. Their first commercial product, Ohtuvaire (ensifentrine), is an inhaled maintenance treatment for COPD that uniquely combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The treatment shows potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases.
Verona Pharma reports strong performance for their newly launched COPD treatment Ohtuvayre (ensifentrine), with approximately $36 million in net product sales for Q4 2024 and $42 million for full year 2024. The drug, launched after FDA approval in June 2024, has gained significant traction with over 3,500 unique healthcare professionals prescribing it and more than 16,000 prescriptions filled in 2024.
Key achievements include approximately 45% of Tier 1 HCPs prescribing Ohtuvayre, monthly prescription growth exceeding 35% in Q4, and about one-third of prescriptions being refills. The company maintains approximately two weeks of inventory at specialty pharmacies and reports strong cash position of approximately $400 million as of December 31, 2024.
Verona Pharma (Nasdaq: VRNA) announces its participation in two major healthcare investor conferences in December 2024. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 12:00 p.m. ET, and at the 7th Annual Evercore HealthCONx Conference in Miami on December 4 at 3:00 p.m. ET. Webcasts of both presentations will be available on the company's website. Verona Pharma specializes in developing therapies for chronic respiratory diseases, with their first commercial product Ohtuvayre™ (ensifentrine) being a dual-action COPD treatment.
Verona Pharma (Nasdaq: VRNA) announces its participation in the upcoming Jefferies London Healthcare Conference. The company's senior management will deliver a company overview on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT.
A webcast of the presentation will be accessible through the Events and Presentations section on the Investors page of Verona Pharma's website. The company has provided contact information for investor relations, US investor enquiries, and international/US media enquiries for those seeking additional information.
Verona Pharma reported strong Q3 2024 results, with Ohtuvayre™ (ensifentrine) launch generating $5.6 million in net sales during its first seven weeks. October sales exceeded Q3 performance, with over 5,000 prescriptions filled and 2,200 unique prescribers across COPD patients. The company initiated two Phase 2 trials: a dose-ranging trial with glycopyrrolate and a trial for non-cystic fibrosis bronchiectasis. Cash position stood at $336.0 million, expected to fund operations through 2026. Q3 expenses increased with R&D at $10.6 million and SG&A at $35.2 million, resulting in a net loss of $43.0 million.
